Engineered probiotics for targeted therapy of inflammatory bowel disease as well as construction method and application of engineered probiotics

By introducing a recombinant expression system into probiotics, it improves its targeted colonization ability in the intestinal tract of IBD patients and reduces inflammation through antibody release, it solves the side effects and poor specificity of traditional drugs and probiotics for treating IBD, and achieves continuous , controllable therapeutic effects.

CN119040233APending Publication Date: 2024-11-29XIDIAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411165418.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Traditional drugs are used to treat inflammatory bowel disease. IBD has major side effects and cannot continuously relieve symptoms, and poor probiotic colonization ability and disease specificity.

Method used

Designed an engineered probiotic to improve the intestinal colonization ability in IBD patients by introducing a recombinant expression system, including cell surface display protein-encoding genes and heparin sulfate proteoglycan-specific adhesion protein-encoding genes, and through Anti-cellular inflammatory factors antibody genes achieve sustained and controlled release of antibodies to alleviate intestinal inflammation.

Benefits of technology

It significantly improves the targeted colonization ability and treatment specificity of probiotics in the intestines of IBD patients, achieves continuous and controllable inflammation reduction and intestinal homeostasis reconstruction, and improves the long-term therapeutic effect of IBD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040233A_ABST
    Figure CN119040233A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of microorganisms and biology, and discloses engineered probiotics for targeted therapy of inflammatory bowel diseases as well as a construction method and application of the engineered probiotics. The engineered probiotics provided by the invention have good intestinal colonization ability and good IBD intestinal lesion site targeting, and can be specifically colonized in an inflammatory site in the intestinal tract of a patient for long-term continuous treatment, so that the long-term treatment effect of IBD is improved. In addition, the engineering bacterium provided by the invention also has the advantages of good safety, controllable treatment and the like, and has clinical application potential.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms and biotechnology, and in particular to an engineered probiotic for targeted treatment of inflammatory bowel disease and a construction method and application thereof. Background Art

[0002] Inflammatory bowel disease (IBD), mainly including ulcerative colitis (UC) and Crohn's disease (CD), is a global chronic intestinal inflammatory disease with millions of patients. IBD is incurable, recurrent and progressive, and can cause disability, which imposes a serious medical burden on patients. Traditional drugs for the treatment of IBD in clinic include glucocorticoids, aminosalicylates, and immunosuppressants. These drugs improve symptoms and maintain remission by eliminating inflammation, but they cannot cure IBD. In medical practice, it is found that traditional drugs can only induce sustained remission of IBD in a small number of patients, and long-term use has great side effects and a high recurrence rate. In addition to traditional drugs, biological agents are also used in the clinic to treat IBD. Biological agents exert their therapeutic effects by blocking specific inflammatory factors, but up to 40% of patients still do not respond to initial treatment; among patients who initially respond, 13%-46% of patients lose their response in the following year.

[0003] It is crucial to develop new therapeutic drugs with long-lasting effects, high efficacy, and few toxic side effects. Studies have shown that IBD is associated with intestinal mucosal barrier dysfunction and intestinal microbial disturbances. Due to the advantages of probiotic-mediated IBD treatment in repairing intestinal barrier recovery, intestinal flora homeostasis, and regulating intestinal mucosal immunity, the use of probiotics to alleviate or treat IBD has become an effective strategy for IBD treatment. However, traditional probiotic treatments are difficult to colonize in the intestine, have limited concentrations at the site of the disease, and are not disease-specific. For example, the probiotic drugs currently on the market The intestinal colonization ability and disease specificity of Atenin and VSL-3 are limited, mainly because the original intestinal microbiome has colonization resistance to supplemented strains, and the changed gastrointestinal environment of IBD patients also makes probiotic colonization more difficult. Some clinical trials currently underway have also revealed that the efficacy of probiotics is not significant, and the ability to target intestinal lesions in IBD patients is poor. Therefore, it is necessary to develop an engineered probiotic treatment strategy that can target inflammatory bowel disease. Summary of the invention

[0004] The purpose of the present invention is to overcome the problems of the existing technology in the treatment of IBD, such as the large side effects of traditional drugs, the inability to continuously relieve symptoms, the poor intestinal colonization ability and disease specificity of probiotic products, and to provide an engineered probiotic for targeted treatment of inflammatory bowel disease and its construction method and application. The engineered probiotic provided by the present invention can be well colonized in the intestine of IBD patients and target the lesion site, and the expression and release of antibodies can be controlled by oral arabinose, so as to reduce chronic intestinal inflammation and achieve continuous and controllable IBD treatment.

[0005] In order to achieve the above objectives, the first aspect of the present invention provides an engineered probiotic, which includes a probiotic and a recombinant expression system introduced into the probiotic, wherein the recombinant expression system includes a gene encoding a cell surface display protein and a gene encoding a heparin sulfate proteoglycan-specific adhesion protein.

[0006] The second aspect of the present invention provides a method for constructing an engineered probiotic, characterized in that the method comprises introducing a recombinant expression system into the probiotic, wherein the recombinant expression system comprises a gene encoding a cell surface display protein and a gene encoding a heparan sulfate proteoglycan-specific adhesion protein.

[0007] The third aspect of the present invention provides a pharmaceutical composition, which comprises the engineered probiotics described in the first aspect as an active ingredient, or the pharmaceutical composition comprises the engineered probiotics constructed according to the method described in the second aspect as an active ingredient.

[0008] The fourth aspect of the present invention provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of a drug for treating inflammatory bowel disease.

[0009] The fifth aspect of the present invention provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of drugs and / or functional health products, wherein the drugs and / or functional health products are used to repair the intestinal barrier, and / or to improve the homeostasis of intestinal flora, and / or to regulate intestinal mucosal immunity.

[0010] The sixth aspect of the present invention provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in improving the long-term efficacy of inflammatory bowel disease.

[0011] Through the above technical solution, the present invention can at least achieve the following beneficial effects:

[0012] (1) The present invention designs and constructs an engineered probiotic that can anchor adhesion proteins that specifically bind to HSPG on the cell surface, greatly improving the targeted colonization ability of the bacteria in the intestines of IBD patients and making it have a higher IBD treatment specificity. In a further preferred design scheme, an antibody gene for anti-inflammatory factors is also introduced to enable the engineered probiotic to stably and continuously release antibodies in the intestines of IBD patients, slow down the occurrence of intestinal inflammation, reshape intestinal homeostasis, and improve long-term efficacy. In a preferred case, the antibody gene for anti-inflammatory factors is expressed by an inducible promoter to achieve controllable release of antibodies, which can be released more specifically in accordance with medical test results.

[0013] (2) The base bacteria (such as Nissle1917, Bifidobacterium or Clostridium butyricum, etc.) selected for the engineered probiotics provided by the present invention are intestinal probiotics, thereby making the engineered bacteria of the present invention safer and reducing unnecessary side effects.

[0014] (3) The engineered probiotics provided by the present invention can be used as oral probiotics, which are easy to use and help improve patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 It is a diagram showing the working principle of the engineered probiotics of the present invention;

[0016] Figure 2 The plasmid map of the plasmid pUC19-ClyA-HlpA-pelB-TNF to be constructed in Example 1;

[0017] Figure 3 The PCR results of the plasmid pUC19-ClyA-HlpA-pelB-TNF and the corresponding engineered bacteria in Example 1;

[0018] Figure 4 This is a BCA quantification graph of TNF-α antibody produced by the engineered bacteria under the induction of different arabinose concentrations in Example 1;

[0019] Figure 5 The result table of predicting the secretion efficiency of 21 commonly used signal peptides in Example 1;

[0020] Figure 6 This is a BCA quantitative graph of the secretion of TNF-α antibodies to the extracellular space by different signal peptides in Example 1;

[0021] Figure 7 The BCA quantification graph of HlpA protein produced by the engineered bacteria containing different constitutive promoters in Example 1;

[0022] Figure 8 This is a quantitative diagram of the display efficiency of proteins displayed on the surfaces of different cells in Example 1;

[0023] Fig. 9 is a diagram showing the adhesion of the engineered bacteria Ep-TH in Example 2 to cell lines with different HSPG expression levels;

[0024] Fig.10 The IBD development detection results of the normal group, model group, EcN group and Ep-TH group of mice in Example 3 are shown in Figure 3, including A: comparison of weight changes of mice in each group; B: comparison of DAI score changes of mice in each group; C: comparison of colon length of mice in each group; D: comparison of colon immunohistochemical staining analysis of mice in each group;

[0025] Fig.11 This is a graph showing the colonization of the bacteria in the inflamed colon and the non-inflamed colon over time after the mice were treated with the engineered bacteria Ep-TH and the unengineered EcN in Example 4;

[0026] Fig.12 It is a diagram of the microbial composition of mice in the normal group, model group, EcN group and Ep-TH group in Example 5, including A: principal component analysis (PCA) of the beta diversity of the intestinal flora of each group of mice; B: Chao index of the intestinal flora of each group of mice; C: Shanon index of the intestinal flora of each group of mice; D: Simpson index of the intestinal flora of each group of mice; E: stacked diagram of the flora distribution at the phylum level of each group of mice; F: stacked diagram of the flora distribution at the genus level of each group of mice;

[0027] Fig.13 The CD development detection result diagram of the normal group, model group, EcN group and Ep-TH group of mice in Example 6 includes A: comparison of weight changes of mice in each group; B: comparison of DAI score changes of mice in each group; C: comparison of colon length of mice in each group; D: comparison of intestinal ulcer registration scores of mice in each group; E: comparison of intestinal ulcer area of ​​mice in each group; F: comparison of perianal secretions of mice in each group; GJ: comparison of cytokine IL-6, TNF-α, IL-1β and IL-10 expression;

[0028] Fig.14 This is a graph showing the evaluation results of the preventive effect of colitis in the normal group, DSS group, EcN group and Ep-TH group of mice in Example 7, including A: comparison of weight changes of mice in each group; B: comparison of colon length of mice in each group; C: comparison of DAI score changes of mice in each group; D: comparison of spleen index of mice in each group. DETAILED DESCRIPTION

[0029] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0030] In the present invention, unless otherwise specified, "IBD" is an abbreviation of "inflammatory bowel disease", which have the same meaning; "TNF-α" is an abbreviation of "tumor necrosis factor α", which have the same meaning; "HSPG" is an abbreviation of "heparin sulfate proteoglycan", which have the same meaning; "EcN" is an abbreviation of "Escherichia coli Nissle 1917", which have the same meaning; "engineered bacteria" is an abbreviation of "engineered probiotics", which have the same meaning; the above groups of terms with the same meaning can be used interchangeably.

[0031] The inventors of the present invention have found in their research that the expression of heparan sulfate proteoglycans (HSPGs) in the intestines of IBD patients is significantly increased. On this basis, the inventors cleverly designed a construct that anchors the adhesion protein that can specifically bind to HSPG on the cell surface through cell surface display protein. After the construct is introduced into the chassis cells, the HSPG-specific adhesion protein expressed by the obtained engineered bacteria is stably anchored on the surface of the engineered bacteria, so that it can specifically adhere to the intestines of IBD patients, especially targeted adhesion to the site of inflammation in the intestine, and effectively improve the targeted colonization ability of the engineered bacteria through the interaction between adhesion protein and HSPG.

[0032] Based on the above findings, the first aspect of the present invention provides an engineered probiotic, comprising a probiotic and a recombinant expression system introduced into the probiotic, wherein the recombinant expression system comprises a gene encoding a cell surface displayed protein and a gene encoding a heparan sulfate proteoglycan-specific adhesion protein.

[0033] Surface display technology connects the gene sequence of the target protein with the gene sequence of the carrier protein and then introduces it into the host cell for expression. When the carrier protein is expressed, the target protein is co-expressed and localized on the surface of the host cell. Bacterial surface display proteins are a type of protein that can express target proteins on the surface of bacteria to better realize their functions. They are widely used in many fields such as recombinant bacterial vaccines, biofuel cells, whole-cell catalysts and bioremediation.

[0034] According to a preferred embodiment of the present invention, the cell surface display protein encoding gene can encode a cell surface display protein derived from Streptococcus galloLyticus.

[0035] Preferably, the cell surface display protein encoding gene can encode a cell surface display protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 1. For example, the identity can be 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or can be a range consisting of any two of the above values, or any intermediate value in the range.

[0036] According to a preferred embodiment of the present invention, the cell surface display protein encoding gene can encode a cell surface display protein having an amino acid sequence as shown in SEQ ID NO:1.

[0037] MTEIVADKTVEVVKNAIETADGALDLYNKYLDQVIPWQTFDETIKELSRFKQEYSQAASVLVGDIK

[0038] TLLMDSQDKYFEATQTVYEWCGVATQLLAAYILLFDEYNEKKASAQKDILIKVLDDGITKLNEAQK

[0039] SLLVSSQSFNNASGKLLALDSQLTNDFSEKSSYFQSQVDKIRKEAYAGAAAGVVAGPFGLIISYSIAA

[0040] GVVEGKLIPELKNKLKSVQNFFTTLSNTVKQANKDIDAAKLKLTTEIAAIGEIKTETETTRFYVDYDDLMLSLLKEAAKKMINTCNEYQKRHGKKTLFEVPEV(SEQ ID NO:1)

[0041] Preferably, the cell surface display protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 2. For example, the identity can be 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or can be a range consisting of any two of the above values, or any intermediate value in the range.

[0042] According to a preferred embodiment of the present invention, the nucleotide sequence of the gene encoding the cell surface displayed protein is as shown in SEQ ID NO:2.

[0043] ATGACTGAAATCGTTGCAGATAAAACGGTAGAAGTAGTTAAAAACGCAATCGAAACCGCAGAT

[0044] GGAGCATTAGATCTTTATAATAAATATCTCGATCAGGTCATCCCCTGGCAGACCTTTGATGAAA

[0045] CCATAAAAGAGTTAAGTCGCTTTAAACAGGAGTATTCACAGGCAGCCTCCGTTTTAGTCGGCGA

[0046] TATTAAAACCTTACTTATGGATAGCCAGGATAAGTATTTTGAAGCAACCCAAACAGTGTATGAA

[0047] TGGTGTGGTGTTGCGACGCAATTGCTCGCAGCGTATATTTTGCTATTTGATGAGTACAATGAGA

[0048] AGAAAGCATCCGCCCAGAAAGACATTCTCATTAAGGTACTGGATGACGGCATCACGAAGCTGA

[0049] ATGAAGCGCAAAAATCCCTGCTGGTAAGCTCACAAAGTTTCAACAACGCTTCCGGGAAACTGC

[0050] TGGCGTTAGATAGCCAGTTAACCAATGATTTTTCAGAAAAAAGCAGCTATTTCCAGTCACAGGT

[0051] AGATAAAATCAGGAAGGAAGCATATGCCGGTGCCGCAGCCGGTGTCGTCGCCGGTCCATTTGG

[0052] ATTAATCATTTCCTATTCTATTGCTGCGGGCGTAGTTGAAGGAAAACTGATTCCAGAATTGAAG

[0053] AACAAGTTAAAATCTGTGCAGAATTTCTTTACCACCCTGTCTAACACGGTTAAACAAGCGAATA

[0054] AAGATATCGATGCCGCCAAATTGAAATTAACCACCGAAATAGCCGCCATCGGTGAGATAAAAA

[0055] CGGAAACTGAAACAACCAGATTCTACGTTGATTATGATGATTTAATGCTTTCTTGCTAAAAGA

[0056] AGCGGCCAAAAAAATGATTAACACCTGTAATGAGTATCAGAAAAGACACGGTAAAAAGACACTCTTTGAGGTACCTGAAGTC(SEQ ID NO:2)

[0057] According to a preferred embodiment of the present invention, the heparan sulfate proteoglycan specific adhesion protein encoding gene may encode a heparan sulfate proteoglycan specific adhesion protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 3. For example, the identity may be 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or may be a range consisting of any two of the above values, or any intermediate value in the range.

[0058] According to a preferred embodiment of the present invention, the heparan sulfate proteoglycan specific adhesion protein encoding gene can encode the heparan sulfate proteoglycan specific adhesion protein HlpA whose amino acid sequence is as shown in SEQ ID NO: 3. MANKQDLIAKVAEATELTKKDSAAAVDAVFSTIEAFLAEGEKVQLIGFGNFEVRERAARKGRNPQTGAEIEIAASKVPAFKAGKALKDAVK (SEQ ID NO: 3)

[0059] Preferably, the heparin sulfate proteoglycan-specific adhesion protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 4. For example, the identity can be 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or can be a range consisting of any two of the above values, or any intermediate value in the range.

[0060] Preferably, the nucleotide sequence of the heparin sulfate proteoglycan-specific adhesion protein encoding gene is as shown in SEQ ID NO:4.

[0061] ATGGCTAACAAACAAGATTTAATCGCAAAGGTTGCAGAAGCAACTGAATTGACTAAAAAAGAT

[0062] TCAGCAGCAGCAGTTGATGCCGTGTTTTCTACAATCGAAGCTTCCTTGCTGAAGGTGAAAAAG

[0063] TACAATTGATCGGTTTTGGTAACTTCGAAGTACGCGAACGTGCAGCTCGTAAAGGTCGTAACCC

[0064] ACAAACTGGTGCAGAAATTGAAATTGCAGCTTCAAAAGTTTCCAGCCTTCAAAGCTGGTAAAGCTCTTAAAGACGCTGTTAAA(SEQ ID NO:4)

[0065] The inventors also found that the expression of pro-inflammatory cytokines such as TNF-α in the blood, epithelial tissue and feces of IBD patients was significantly increased, which led to long-term and chronic inflammation in the intestines of IBD patients. The presence of this inflammation also changed the intestinal environment of patients, destroyed the stability of intestinal flora and intestinal mucosal immunity, and made IBD recurrent and difficult to cure. On the basis of the above-mentioned engineered bacteria, the inventors further introduced anti-pro-inflammatory cytokine antibody encoding genes into the construct, so that the engineered bacteria can be stably colonized in the intestines of IBD patients while continuously releasing antibodies, reducing intestinal inflammation, thereby achieving intestinal barrier repair, rebuilding intestinal flora homeostasis, regulating intestinal mucosal immunity, etc., and improving the therapeutic effect of IBD.

[0066] According to a preferred embodiment of the present invention, the recombinant expression system further comprises at least one of a promoter, a signal peptide encoding gene and an anti-inflammatory cytokine antibody encoding gene.

[0067] Preferably, the promoter comprises an arabinose promoter.

[0068] More preferably, the nucleotide sequence of the arabinose promoter is as shown in SEQ ID NO:5.

[0069] AAGAAAACCAATTGTCCATATTGCATCAGACATTGCCGTCACTGCGTCTTTTACTGGCTCTTCG

[0070] CTAACCAAACCGGTAACCCCGCTTATTAAAAGCATTCTGTAACAAAGCGGGACCAAAGCCATG

[0071] ACAAAAACGCGTAACAAAAGTGTCTATAATCACGGCAGAAAAGTCCACATTGATTATTTGCAC

[0072] GGCGTCACACTTTGCTATGCCATAGCATTTTTATCCATAAGATTAGCGGATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCAT(SEQ ID NO:5)

[0073] Preferably, the promoter comprises a constitutive promoter (eg, promoter P J23103 , P J23117 , P J23114 , P J23105 , P J23110 wait).

[0074] More preferably, the constitutive promoter comprises a nucleotide sequence shown in at least one of SEQ ID NOs: 6-10.

[0075] CTGATAGCTAGCTCAGTCCTAGGGATTATGCTAGC (SEQ ID NO: 6, promoter P J23103 )

[0076] TTGACAGCTAGCTCAGTCCTAGGGATTGTGCTAGC (SEQ ID NO: 7, promoter P J23117 )

[0077] TTTATGGCTAGCTCAGTCCTAGGTACAATGCTAGC (SEQ ID NO: 8, promoter P J23114 )

[0078] TTTACGGCTAGCTCAGTCCTAGGTACTATGCTAGC (SEQ ID NO: 9, promoter P J23105 )

[0079] TTTACGGCTAGCTCAGTCCTAGGTACAATGCTAGC (SEQ ID NO: 10, promoter P J23110 )

[0080] Preferably, the signal peptide encoding gene comprises a nucleotide sequence encoding at least one of the signal peptides pelB, bla or mglB. Preferably, the signal peptide encoding gene can encode at least one of the amino acid sequences shown in SEQ ID NOs: 11-13.

[0081] MKYLLPTAAAGLLLLAAQPAMA (SEQ ID NO: 11, signal peptide pelB)

[0082] MSIQHFRVALIPFFAAFCLPVFA (SEQ ID NO: 12, signal peptide bla)

[0083] MNKKVLTLSAVMASMLFGAAAHA (SEQ ID NO: 13, signal peptide mglB)

[0084] More preferably, the signal peptide encoding gene can encode the signal peptide pelB. Preferably, the signal peptide encoding gene comprises the nucleotide sequence shown in SEQ ID NO:14.

[0085] ATGAAGTACCTCCTCCCCACAGCAGCCGCCGGATTGCTATTACTCGCGGCTCAACCCGCAATGG CC(SEQ ID NO:14)

[0086] Preferably, the anti-proinflammatory cytokine antibody is selected from anti-TNF-α antibody and / or IL-23 antibody.

[0087] More preferably, the anti-proinflammatory cytokine antibody encoding gene encodes an antibody having at least 60% identity to the amino acid sequence shown in SEQ ID NO: 15 or 16. For example, the identity can be 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or can be a range consisting of any two of the above values, or any intermediate value in the range.

[0088] According to a preferred embodiment of the present invention, the anti-proinflammatory cytokine antibody encoding gene can encode an antibody having an amino acid sequence as shown in SEQ ID NO: 15 or 16.

[0089] QVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMYWVRQAPGKGLEWVSQINWNGLITKYPDSV KGRFTISRDNAKNTLYLQMNSLKPEDTALYYCARSPSGFNRGQGTQVTVSS (SEQ ID NO: 15, anti-TNF-α antibody)

[0090] QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGIPIFGTANYAQKFQGR VTITADESTSTAYMELSSLRSEDTAVYYCARDRFGLYYYYGMDVWGQGTMVTVSS (SEQ ID NO: 16, IL-23 antibody)

[0091] According to a preferred embodiment of the present invention, the anti-proinflammatory cytokine antibody encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 17 or 18. For example, the identity can be 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, or can be a range consisting of any two of the above values, or any intermediate value in the range.

[0092] Preferably, the nucleotide sequence of the anti-proinflammatory cytokine antibody encoding gene is as shown in SEQ ID NO: 17 or 18.

[0093] CAAGTTCAGCTGGTTGAAAGCGGCGGTGGTCTGGTTCAGCCGGGCGGCAGTCTGCGTCTGAGTT

[0094] GTGCGGCGAGCGGCTTCACCTTCAGCAACTACTGGATGTACTGGGTTCGCCAAGCCCCGGGCA

[0095] AAGGTCTGGAGTGGGTGAGCCAAATCAACTGGAACGGTCTGATCACCAAGTACCCGGACAGCG

[0096] TGAAAGGCCGCTTCACCATCAGCCGCGATAACGCCAAGAACACGCTGTATCTGCAGATGAACA

[0097] GCCTCAAGCCGGAAGATACGGCGCTGTACTACTGCGCCCGCAGCCCAAGCGGCTTTAATCGCGGCCAAGGCACCCAAGTTACCGTTAGCAGC (SEQ ID NO: 17, TNF-α antibody encoding gene)

[0098] CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAG

[0099] CTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGCCATCAGCTGGGTGAGGCAGGCCCCGG

[0100] CCAGGGCCTGGAGTGGATGGGCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAGTTCCA

[0101] GGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCT

[0102] GAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGACAGGTTCGGCCTGTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC (SEQ ID NO: 18, IL-23 antibody encoding gene)

[0103] According to a preferred embodiment of the present invention, the probiotics are selected from at least one of Escherichia coli, Bifidobacterium and Clostridium butyricum.

[0104] Preferably, the probiotic is selected from at least one of Escherichia coli Nissle1917, Bifidobacterium CICC 6071 and Clostridium butyricum CCTCC AB 2010154.

[0105] According to a particularly preferred embodiment of the present invention, the engineered bacteria include probiotics, and a recombinant expression system (i.e., a construct) introduced with the probiotics, wherein the recombinant expression system includes: a gene encoding a cell surface display protein ClyA, a gene encoding a heparin sulfate proteoglycan-specific adhesion protein HlpA, a gene encoding a signal peptide pelB, a gene encoding a TNF-α or IL-23 antibody, an arabinose promoter, and a constitutive promoter P J23105 In the engineered bacteria, HlpA is anchored to the surface of the engineered bacteria through ClyA, thereby improving its colonization ability in the intestines of IBD patients, and using an arabinose promoter to control the expression of TNF-α or IL-23 antibody encoding genes, so that the expression of TNF-α or IL-23 antibodies can be initiated by oral administration of arabinose while taking the probiotics, thereby achieving controlled release of the antibodies.

[0106] Preferably, the probiotic is selected from at least one of Escherichia coli Nissle1917, Bifidobacterium CICC 6071 and Clostridium butyricum CCTCC AB 2010154.

[0107] Preferably, the gene encoding the cell surface displayed protein ClyA is as shown in SEQ ID NO:2.

[0108] Preferably, the gene encoding the heparin sulfate proteoglycan-specific adhesion protein HlpA is as shown in SEQ ID NO:4.

[0109] Preferably, the signal peptide pelB encoding gene is as shown in SEQ ID NO:14.

[0110] Preferably, the TNF-α antibody encoding gene is as shown in SEQ ID NO:17.

[0111] Preferably, the IL-23 antibody encoding gene is as shown in SEQ ID NO:18.

[0112] Preferably, the nucleotide sequence of the arabinose promoter is as shown in SEQ ID NO:5.

[0113] Preferably, the constitutive promoter P J23105 The nucleotide sequence is shown in SEQ ID NO:9.

[0114] When the coding genes and gene elements of the above preferred nucleotide sequences are selected in the construct, the obtained engineered bacteria can better colonize in the intestines of IBD patients and have a better IBD treatment effect.

[0115] The second aspect of the present invention provides a method for constructing an engineered probiotic, the method comprising introducing a recombinant expression system into the probiotic, the recombinant expression system comprising a gene encoding a cell surface display protein and a gene encoding a heparan sulfate proteoglycan-specific adhesion protein.

[0116] Preferably, the recombinant expression system further comprises at least one of a promoter, a signal peptide encoding gene and an anti-inflammatory cytokine antibody encoding gene.

[0117] The characteristics of the probiotics, recombinant expression system, and the cell surface display protein encoding gene, heparan sulfate proteoglycan-specific adhesion protein encoding gene, promoter, signal peptide encoding gene, and anti-inflammatory cytokine antibody encoding gene involved in the above method are as described above and will not be repeated here.

[0118] The present invention has no specific limitation on the method of introducing the recombinant expression system into the probiotics and the method of constructing the recombinant expression system. Any method in the art that can achieve the above purpose can be applied to the present invention.

[0119] The third aspect of the present invention provides a pharmaceutical composition, which comprises the engineered probiotics described in the first aspect as an active ingredient, or the pharmaceutical composition comprises the engineered probiotics constructed according to the method described in the second aspect as an active ingredient.

[0120] In the pharmaceutical composition provided by the present invention, the engineered bacteria provided by the present invention may be used as the sole active ingredient, or other ingredients (capable of being used for the treatment of IBD) may be added together with the engineered bacteria of the present invention as active ingredients.

[0121] According to some preferred embodiments of the present invention, the pharmaceutical composition further comprises other active ingredients.

[0122] Preferably, the other active ingredients are selected from at least one of glucocorticoids, aminosalicylate, immunosuppressants and other probiotic preparations.

[0123] According to a preferred embodiment of the present invention, the pharmaceutical composition further comprises excipients. Excipients refer to ingredients in the pharmaceutical composition that do not function as active ingredients themselves, such as ingredients used to assist active ingredients in maintaining their activity or promoting their activity, or ingredients used for purposes such as molding and storage of the pharmaceutical composition.

[0124] Preferably, the auxiliary material includes at least one of a buffer, a protective agent, a stabilizer, a coating agent and a flavoring agent.

[0125] According to some preferred embodiments of the present invention, the pharmaceutical composition may further contain arabinose. The purpose of arabinose is to promote the expression of antibody genes carried by engineered probiotics. The arabinose can be mixed with other ingredients in the pharmaceutical composition to form a drug together, or it can be packaged separately. In order to control the expression of antibody genes of engineered strains and achieve controlled release of antibodies, it is preferred that the arabinose is packaged (and used) separately.

[0126] The fourth aspect of the present invention provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of a drug for treating inflammatory bowel disease.

[0127] According to a preferred embodiment of the present invention, the drug is an oral preparation, such as an oral probiotic preparation (such as an oral liquid probiotic dispersion, an oral probiotic freeze-dried powder, etc.).

[0128] The present invention has no particular limitation on the specific process and method for preparing drugs using the engineered probiotics or pharmaceutical compositions provided by the present invention. Any method in the art that can be used to prepare drugs containing (active) probiotics can be applied to the present invention.

[0129] For example, the above-mentioned medicine can be prepared by making the engineered probiotics provided by the present invention into (active) bacterial powder / liquid. The method of preparing bacterial powder can include freeze drying and other drying methods that can retain the activity of the bacteria. The method of preparing bacterial liquid can include culturing the engineered probiotics provided by the present invention and packaging the obtained culture liquid; or dispersing the bacterial powder into a liquid system (that can retain the activity of the bacteria).

[0130] According to some preferred embodiments of the present invention, the moisture content of the bacterial powder is preferably no more than 5% by weight, for example, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01%, 0% by weight, or a range consisting of any two of the above values, or any intermediate value within the range.

[0131] Preferably, the bacterial powder may also contain auxiliary materials, such as freeze-drying protective agents, buffers, etc.

[0132] According to some embodiments of the present invention, the medicine may only include the bacterial powder as an active ingredient. For example, the bacterial powder can be directly made into capsules, granules, tablets, powders and other dosage forms as medicine.

[0133] According to some embodiments of the present invention, the drug may further include other ingredients (as active ingredients together with the bacterial powder, or as excipients). The present invention has no particular restrictions on the other ingredients specifically selected in the drug, and any ingredient that can be used in the art for the preparation of drugs for the treatment of IBD can be applied to the present invention, and its specific dosage can be selected and adjusted according to actual conditions.

[0134] For example, according to one embodiment of the present invention, the drug may include bacterial powder, folic acid, vitamin B12 and mannitol. Preferably, relative to 0.5 g bacterial powder (the content of engineered probiotics is not less than 1×10 6 CFU / g), folic acid content is 0.1-1mg, vitamin B12 content is 0.1-1μg, and mannitol content is 0.1-1mg.

[0135] The fifth aspect of the present invention provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of drugs and / or functional health products, wherein the drugs and / or functional health products are used to repair the intestinal barrier, and / or to improve the homeostasis of intestinal flora, and / or to regulate intestinal mucosal immunity.

[0136] In the present invention, "repairing the intestinal barrier" refers to restoring or enhancing the function of the damaged intestinal barrier of the subject, such as enhancing the intestinal barrier function of patients with intestinal diseases, especially IBD patients. Specific manifestations may include restoring the crypts and mucosal layer, thickening the mucus layer, and repairing and / or maintaining the integrity of the colon epithelium.

[0137] In the present invention, "improving intestinal flora homeostasis" means restoring the intestinal flora composition of the subject to homeostasis, for example, restoring the intestinal flora of patients with intestinal diseases, especially IBD patients, to homeostasis, so as to be close to the intestinal flora composition of healthy people. Specific manifestations may include increased α-richness and β-richness of the intestinal flora, increased probiotics, reduced harmful bacteria, etc.

[0138] In the present invention, "regulating intestinal mucosal immunity" refers to restoring the balance of the intestinal mucosal immune system that was originally imbalanced in the subject, such as restoring the balance of the intestinal mucosal immune system in patients with intestinal diseases, especially IBD patients. Specific manifestations may include reducing the occurrence of intestinal inflammation, slowing down the development of intestinal inflammation, protecting the intestinal mucosa, etc. through the production of anti-inflammatory cytokines and the regulation of inflammatory cells.

[0139] Furthermore, the present invention also provides the use of the engineered probiotics described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in repairing the intestinal barrier, and / or improving the homeostasis of intestinal flora, and / or regulating intestinal mucosal immunity, etc.

[0140] The engineered bacteria provided by the present invention can stably colonize in the intestine of IBD patients and continuously release antibodies against cellular inflammatory factors, thereby being able to stably help IBD patients slow down the occurrence of intestinal inflammation in a long-term manner, promote the reconstruction of intestinal homeostasis, thereby avoiding recurrence of the disease and improving long-term efficacy. In the case of introducing an inducible promoter such as an arabinose promoter into the engineered bacteria, the engineered bacteria can also be artificially intervened (such as oral arabinose) to express antibodies, making the treatment process more controllable and improving the long-term and overall efficacy of IBD.

[0141] Therefore, the sixth aspect of the present invention provides the use of the engineered bacteria described in the first aspect, or the engineered probiotics constructed according to the method described in the second aspect, or the pharmaceutical composition described in the third aspect in improving the long-term efficacy of inflammatory bowel disease.

[0142] In the present invention, "improving the long-term efficacy of inflammatory bowel disease" means that the symptoms of IBD patients can be treated and alleviated over a longer period of time, reducing the recurrence of the disease, and improving the stability and continuity of the treatment effect.

[0143] The present invention will be described in detail below by way of examples. It should be understood that the following examples are only used to further explain and illustrate the content of the present invention by way of example, and are not intended to limit the present invention.

[0144] In the following examples, unless otherwise specified, the reagents and materials used were all commercial products purchased from regular chemical or biological reagent / material suppliers, and the purity of the reagents was analytical grade.

[0145] Example 1

[0146] This example is used to illustrate the construction of the engineered bacteria provided by the present invention and the results of its performance testing.

[0147] (I) Construction of engineered bacteria

[0148] 1. Construction of recombinant plasmid

[0149] Synthesis of recombinant gene sequences: Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize anti-TNF-α and the optimized signal peptide PelB gene sequence. J23105 (SEQ ID NO:9), ClyA protein encoding gene (SEQ ID NO:2), HlpA encoding gene (SEQ ID NO:4), promoter PBAD (arabinose promoter, SEQ ID NO:5), signal peptide pelB encoding gene (SEQ ID NO:14) and TNF-α antibody encoding gene (SEQ ID NO:17) were spliced ​​through the high-efficiency cloning plasmid pMD-18T and transformed into the plasmid recipient bacteria DH5α to obtain the recombinant bacteria pMD-18T-ClyA-HlpA-pelB-TNF-DH5α containing the recombinant cloning plasmid.

[0150] Synthesis of recombinant plasmid: The whole genome gene extracted from the recombinant clone pMD-18T-ClyA-HlpA-pelB-TNF-DH5α was used as a template to obtain the target sequence P by full-length PCR synthesis reaction. J23105 -ClyA-HlpA-PBAD-pelB-TNF. The target sequence was ligated into expression plasmids pUC19 and pMT107, respectively, to obtain recombinant plasmids pUC19-ClyA-HlpA-pelB-TNF and pMT107-ClyA-HlpA-pelB-TNF. Figure 2 The plasmid map of the plasmid pUC19-ClyA-HlpA-pelB-TNF is shown in Figure 1. The above recombinant plasmids were transformed into the plasmid recipient bacteria DH5α to obtain the corresponding recombinant bacteria.

[0151] 2. Construction of engineered bacteria

[0152] 2.1 Construction of engineered bacteria using Escherichia coli Nissle 1917 as the chassis

[0153] The recombinant plasmid pUC19-ClyA-HlpA-pelB-TNF was extracted from the recombinant bacteria using an endotoxin-free plasmid mini-extraction kit (Tiangen Biochemical Technology Co., Ltd.), and introduced into competent E. coli Nissle1917 by heat shock method. After transformation, the bacterial solution was spread on LB solid plates containing 50 mg / L ampicillin and cultured at 37°C overnight. The single colony on the above plate was picked and cultured, and the plasmid was extracted and the gene fragment was verified by PCR amplification. The positive clone strain obtained was named Ep-TH.

[0154] Figure 3 These are the PCR results for plasmid pUC19-ClyA-HlpA-pelB-TNF and the corresponding engineered bacteria Ep-TH. The target fragment size is about 2000 bp. There is no target band without adding primers. The primer + plasmid group has an obvious band at 2000 bp, proving that the plasmid was successfully constructed. The band appears in the primer + bacteria group, proving that the engineered bacteria were successfully constructed.

[0155] 2.2 Construction of engineered bacteria based on Bifidobacterium

[0156] The construction method was the same as 2.1, except that the chassis cells were replaced with Bifidobacterium CICC 6071 competent cells, and the transformation method was changed to electroporation. The obtained strain was named BL-TH.

[0157] 2.3 Construction of engineered bacteria based on Clostridium butyricum

[0158] The construction method was the same as that in 2.1, except that the chassis cells were replaced with Clostridium butyricum CCTCC AB 2010154 competent cells, the transferred plasmid was pMT107-ClyA-HlpA-pelB-TNF, and the obtained strain was named CB-TH.

[0159] (II) Performance testing of engineered bacteria

[0160] 1. Detection of arabinose response performance of engineered bacteria

[0161] Ep-TH was inoculated into LB liquid medium containing ampicillin and cultured at 37°C overnight. The bacteria were cultured until OD 600 When the concentration of arabinose was 0.8, different concentrations of arabinose were added and induced at 37°C for 24 h. The total bacterial protein was extracted by TCA-acetone precipitation method, and the antibodies produced by the engineered bacteria in response to arabinose were quantitatively analyzed by BCA method. Figure 4 As shown, the engineered strain was able to respond sensitively to the presence of arabinose, and this response showed a clear concentration dependence.

[0162] BL-TH and CB-TH were tested using the same method and obtained similar results, indicating that they can both respond sensitively to arabinose and show a clear concentration dependence.

[0163] 2. Detection of exocytosis efficiency of engineered bacteria

[0164] 21 commonly used signal peptides were selected for use in the engineered probiotics provided by the present invention, and the values ​​of Sec / SPI, Sec / SPII and Tat / SPI of the signal peptides were calculated by SignalP 5.0 to predict the secretion efficiency of the signal peptides. Figure 5 As shown, the secretion efficiency of bla, mglB and pelB signal peptides was better than that of the other 18 signal peptides.

[0165] The engineered bacteria were constructed according to the above construction method, except that the signal peptide sequences were changed to bla (SEQ ID NO: 12) and mglB (SEQ ID NO: 13), respectively. The obtained engineered bacteria were inoculated in LB liquid medium containing ampicillin and cultured at 37°C overnight. The bacteria were cultured until OD 600 When the concentration of arabinose was 0.8, 0.5% arabinose was added, induced at 37°C for 12h, centrifuged at 4000rpm for 10min, the precipitate was resuspended and ultrasonically broken until the resuspended liquid was clear, centrifuged again and the supernatant was taken. The protein content in the LB supernatant and the supernatant after the precipitate was broken was measured respectively. The results are shown in Figure 6 As shown, the exocytosis efficiency of pelB signal peptide is better than that of bla and mglB signal peptides. Further codon optimization of pelB signal peptide can further improve the secretion efficiency.

[0166] 3. Detection of HlpA constitutive expression efficiency

[0167] The engineered bacteria were constructed according to the above method, except that the synthesized recombinant gene sequence was ClyA-HlpA-His, and the promoter was replaced by P J23103 (SEQ ID NO:6), P J23117 (SEQ ID NO:7), P J23114 (SEQ ID NO: 8), P J23105 (SEQ ID NO:9), P J23110 (SEQ ID NO: 10).

[0168] The engineered bacteria were inoculated in LB liquid medium containing ampicillin and cultured overnight at 37°C. After the culture was completed, the bacterial precipitate was separated by centrifugation and the supernatant was discarded. Then, the bacterial precipitate was resuspended and ultrasonically disrupted. The disrupted sample was purified by His-tag protein purification magnetic beads (Suzhou Beaver Biotechnology). The purified protein was quantitatively analyzed by the BCA method. Figure 7 The effects of different constitutive promoters on HlyA expression efficiency are shown.

[0169] 4. Detection of the efficiency of engineered bacterial cell surface display

[0170] The engineered bacteria were constructed according to the above method, except that the synthesized recombinant gene sequences were ClyA-HlpA, INP-HlpA and OmpC-HlpA.

[0171] The engineered bacteria were inoculated in LB liquid medium containing ampicillin and cultured overnight at 37°C. 0.5% arabinose was added. After induction for 12 hours, the cells were harvested and resuspended in buffer. The resuspended cells were incubated with purified green fluorescent protein (GFP) at 30°C for 20 minutes to achieve the binding of GFP to the cell surface. After the incubation, any GFP that was not bound to the cell surface was removed by centrifugation and washing with buffer twice. The whole cell fluorescence was measured in a microplate reader to evaluate and quantify the display ability of the entire bacterial population. The results are shown in Figure 2. Figure 8 As shown, the engineered strain displaying the ClyA-HlpA recombinant gene sequence exhibited a higher fluorescence intensity than the other two recombinant gene sequences (INP-HlpA and OmpC-HlpA), indicating that its cell surface display efficiency was optimal.

[0172] The same method was used, except that Bifidobacterium CICC 6071 and Clostridium butyricum CCTCC AB 2010154 were used as chassis cells, and the same results were obtained.

[0173] Example 2

[0174] This example is used to illustrate the adhesion effect of the engineered bacterial strain provided by the present invention on cell lines with different HSPG expression levels.

[0175] 1. Cell culture: CW2 (human colon adenocarcinoma cell) cells and Caco2 (human colorectal adenocarcinoma cell) cells were cultured in Dulbocco's Modified Eagle Medium containing 10% fetal bovine serum and 1% streptomycin / penicillin at 37° C. and 5% CO 2 .

[0176] 2. CFU count of adherent bacteria: The above two types of cells were counted at 2×10 5 5×10 cells / well were inoculated in a six-well cell culture plate. After culturing for 24 h, the culture medium was replaced with DMEM medium supplemented with 50 mg / L ampicillin. 9 Ep-TH was co-incubated with the two cells for 2 hours. 1% Triton×-100 was added to each well of the cell culture plate and incubated at room temperature for 10 minutes to lyse the cells. The cell lysate was diluted and plated for counting to determine the CFU number of adherent bacteria.

[0177] The results showed that the CFU of Ep-TH-adherent bacteria in Caco2 cells with high HSPG expression was significantly higher than that in CW2 cells with low HSPG expression. The difference in HSPG expression levels between these two cell lines was based on information from the Human Protein Atlas database. Fig. 9 As shown, Ep-TH effectively targeted and specifically enhanced the adhesion to HSPG-overexpressing cells through the HlpA protein displayed on its cell surface.

[0178] The same method was used to detect the ability of the engineered bacteria containing different constitutive promoters obtained in Example 1 to target HSPG. The experimental results showed that the enhanced constitutive promoter can significantly increase the expression level of HlpA protein, thereby enhancing the binding ability of the engineered strain to HSPG. However, the experiment also found that when the HlpA protein is overexpressed on the cell surface, it has an inhibitory effect on the adhesion process, which may be due to the aggregation or structural changes caused by overexpression of the HlpA protein. After systematic screening and evaluation, the constitutive promoter P was selected. J23105 The comprehensive effect of the engineered bacteria is the best. This promoter can express relatively more HlpA protein without causing inhibition, while maintaining the strongest adhesion ability of the engineered strain to HSPG.

[0179] The same method was used to verify the ability of the engineered bacteria containing different cell-displayed proteins obtained in Example 1 to target HSPG. The experimental results showed that ClyA could display more HlpA, thereby more effectively binding to HSPG and achieving more efficient targeting in cells that highly expressed HSPG.

[0180] The targeting of the engineered bacteria BL-TH and CB-TH was tested and verified by the same method, and similar test results were obtained, indicating that the engineered bacteria provided by the present invention have good targeting HSPG ability and good adhesion to HSPG expressing cells. Further tests showed that when Bifidobacterium CICC 6071 and Clostridium butyricum CCTCC AB 2010154 were used as chassis cells, the HSPG targeting ability results obtained by selecting ClyA, INP and OmpC as the corresponding engineered bacteria for cell surface display proteins were similar to the results of the above engineered bacteria using EcN as chassis cells.

[0181] Example 3

[0182] This example is used to illustrate the effect of the engineered bacterial strain provided by the present invention in alleviating the development of DSS-induced UC.

[0183] refer to Figure 1, verifying that the engineered probiotics constructed by the present invention can alleviate the development of UC in IBD model mice by oral administration to the model mice.

[0184] 1. Model construction

[0185] In the animal experiment of this embodiment, 6-8 week old healthy C57BL / 6 mice (purchased from Chongqing Tengxin Biotechnology Co., Ltd.) were selected. After adaptive feeding for 1 week, the mice were randomly divided into four groups as follows:

[0186] Normal group (CTRL group): no treatment, normal feeding;

[0187] DSS group: freely drink 3% dextran sulfate sodium (DSS) solution;

[0188] EcN group: After free drinking of 3% DSS solution for five days, the mice were orally gavaged with Nissle 1917 strain at a dosage of approximately 5×10 9 CFU / piece;

[0189] Ep-TH group: After drinking 3% DSS solution for 5 days, the solution was changed to 0.5 mg / mL arabinose solution. The Ep-TH strain was orally administered to mice at a dosage of about 5 × 10 9 CFU / piece.

[0190] Except for the mice in the normal group, all the mice in each group showed (100%) diarrhea, decreased food intake, decreased body weight, decreased fur gloss and other symptoms, indicating that the inflammatory bowel disease model was successfully established.

[0191] (II) Efficacy of engineered bacteria

[0192] During the modeling period, the weight changes, eating and drinking conditions, hair gloss, mental state, activity conditions, and death of the mice were observed. The weight change results are detailed in Fig.10 (A) The Disease Activity Index (DAI) was used as a quantitative assessment tool, which takes into account the percentage of weight loss, the severity of diarrhea, and the occurrence of blood in the stool. The results are detailed in Fig.10 (B).

[0193] On the 8th day of the gavage operation, the mice in each group were dissected, the colons of the mice were separated, photographed and measured in length. The results are detailed in Fig.10 (C) Hematoxylin-eosin (HE)-stained sections of colon tissue were prepared for pathological and morphological evaluation. The results are detailed in Fig.10 (D).

[0194] As can be seen from the figure, Ep-TH treatment alleviated the trend of weight loss in mice ( Fig.10 ,A), controlled the progression of inflammatory bowel disease ( Fig.10 ,B), the length of the intestinal segment approaches the normal length ( Fig.10 ,C), the colon tissue tended to normal morphology. In addition, the tissue damage in the Ep-TH group was much less than that in the DSS group and the EcN group. The epithelial cells in the Ep-TH treatment group were well-intact, the goblet cells were neatly arranged, the crypt structure was normal, and the inflammatory cell infiltration was almost invisible, which was highly similar to the normal colon tissue morphology ( Fig.10 ,D). These results indicate that Ep-TH exhibits a good therapeutic effect in a mouse colitis model.

[0195] The same method was used to test the IBD efficacy of BL-TH and CB-TH, and both showed Fig.10 Similar results were obtained in .

[0196] Example 4

[0197] This example is used to illustrate the adhesion ability of the engineered bacteria strain provided by the present invention to the inflamed colon of mice.

[0198] During the implementation of Example 3, every 4 hours after gavage, 3 mice in each of the EcN group and Ep-TH group were killed to collect colon segments (including about 1 cm of proximal, middle and distal colon tissues), and mucosal samples were scraped and diluted and plated to count EcN and EP-TH in the samples. Fig.11 (AD in the figure shows the counting results at 4h, 8h, 12h and 24h respectively).

[0199] The results are as follows Fig.11 As shown, within 24 hours after administration, the number of Ep-TH colonies in the colon of IBD model mice was significantly higher than that of EcN that had not been engineered. At the four observation time points, the number of Ep-TH colonization in the inflamed colon area was significantly higher than that in the non-inflamed colon area. This phenomenon shows that the engineered bacteria Ep-TH of the present invention can not only specifically bind to the inflamed colon, but also achieve long-term adhesion at the lesion site, and maintain a high adhesion ability at least after 24 hours.

[0200] The same method was used to detect BL-TH and CB-TH, and both showed the same Fig.11 Similar results.

[0201] Example 5

[0202] This example is used to illustrate the effect of the engineered bacterial strain provided by the present invention on alleviating intestinal flora disorder and restoring intestinal flora function in IBD model mice.

[0203] The experimental groups were set up in the manner of Example 3, and the intestinal flora composition was analyzed. The full-length 16S rRNA gene of the feces of each group of mice was amplified to identify different colony compositions.

[0204] like Fig.12 As shown in Figure 2, after DSS induction, the intestinal flora of mice was disturbed, and the specific manifestations included significant separation of the flora composition of the DSS group compared with the normal group and the Ep-TH group ( Fig.12 ,A), the abundance of bacterial flora decreased ( Fig.12 , B, C, D), the number of probiotics (percentage) decreased, and the number of harmful bacteria (percentage) increased ( Fig.12 ,E,F), and after treating DSS-induced IBD model mice with engineered bacteria Ep-TH, the imbalance of intestinal flora in mice was improved, and the intestinal flora composition developed towards that of normal mice, thereby alleviating enteritis-related symptoms.

[0205] The same method was used to detect BL-TH and CB-TH, and both showed the same Fig.12 Similar results.

[0206] Example 6

[0207] This example is used to illustrate the effect of the Escherichia coli strain provided by the present invention on alleviating the development of TNBS-induced Crohn's disease (CD).

[0208] 1. Model construction

[0209] In the animal experiment of this embodiment, 6-8 week old healthy C57BL / 6 mice (purchased from Chongqing Tengxin Biotechnology Co., Ltd.) were selected. After adaptive feeding for 1 week, the mice were randomly divided into four groups as follows:

[0210] Normal group (CTRL group): no treatment, normal feeding;

[0211] TNBS group: A pre-sensitization experiment was performed on the skin of the back of the mouse neck with 1 volume % TNBS solution (solvent is ethanol) one week in advance to induce immunity in advance, which is conducive to the formal construction of the CD model. Fasting for 12 hours before enema, the catheter was inserted 4 cm into the anus. 150 μL of 1 volume % TNBS solution (solvent is ethanol) was injected into the mouse rectum, and the mouse tail was lifted upside down for 30 seconds to allow the TNBS solution to be evenly distributed in the intestine;

[0212] EcN group: Same as the model group, mice were orally gavaged with EcN strains every other day after TNBS injection, with a dosage of about 5×10 9 CFU / piece;

[0213] Ep-TH group: Same as the wild mushroom group, except that the strain administered intragastrically was the Ep-TH strain.

[0214] After the model was established, mice other than the normal group began to show signs of depression, anorexia, lack of activity, and weight gain.

[0215] The phenomenon of decrease in blood pressure, accompanied by diarrhea and blood in the stool indicated that the model was successful.

[0216] (II) The efficacy of engineered bacteria in alleviating Crohn's disease

[0217] During the modeling and gavage period, the health status of the experimental mice was monitored daily, including counting the number of deaths and weighing the body weight. The results are detailed in Fig.13 (A). In addition, the DAI scoring system was used to comprehensively evaluate the disease progression of mice. The evaluation results are detailed in Fig.13 (B).

[0218] After the 7-day treatment period, the mice were anesthetized to collect blood samples and colon and fistula surrounding tissue. The length of the colon was then measured. Fig.13 (C) The relevant data of colorectal ulcer grade, perianal secretions, ulcer area and other indicators are shown in Fig.13 (D, E, F).

[0219] To further evaluate the extent of inflammatory response, the concentrations of key inflammatory cytokines, including interleukin-6 (IL-6), TNF-α, interleukin-1β (IL-1β), and interleukin-10 (IL-10) in the serum of each group of mice were quantitatively analyzed using enzyme-linked immunosorbent assay (ELISA). Fig.13 (GJ) and provides a scientific basis for the assessment of inflammatory response.

[0220] The results are as follows Fig.13 As shown in the figure, it can be seen that the weight loss trend of mice was alleviated after treatment with engineered bacteria ( Fig.13 ,A), IBD disease activity decreased ( Fig.13 ,B), the length of the colon gradually returns to a near normal physiological range ( Fig.13 ,C), and related indicators such as intestinal ulcer grade score, ulcer area, and perianal secretions were significantly improved ( Fig.13 ,DF); from Fig.13(GJ) It can be seen that compared with the TNBS group, the levels of inflammatory cytokines IL-1β and IL-6 were significantly reduced after engineering bacteria treatment, and the level of anti-inflammatory factor IL-10 was significantly increased after engineering bacteria treatment. Moreover, the effect of the Ep-TH group was significantly better than that of the EcN group. These results show that Ep-TH shows a good therapeutic effect in the mouse Crohn's disease model.

[0221] The same method was used to detect BL-TH and CB-TH, and both showed Fig.13 Similar results.

[0222] Example 7

[0223] This example is used to illustrate that the engineered bacterial strain provided by the present invention can prevent DSS-induced colitis in mice.

[0224] The experimental groups were set up in the same manner as in Example 3, except that before modeling, the DSS group and the Ep-TH group were administered with the corresponding strains for 5 days, with a dosage of 5×10 9 CFU / piece.

[0225] During the modeling process, the weight changes of mice in each group were measured daily. The results are shown in Fig.14 (A). The Disease Activity Index (DAI) is a quantitative evaluation tool used to comprehensively reflect the disease activity of mice. The results are detailed in Fig.14 (B) Seven days after treatment, the mice were anesthetized and sacrificed, and the length of the colon and spleen index were recorded. Fig.14 (CD).

[0226] like Fig.14 As shown, the mice in the Ep-TH group showed less weight loss compared with the other groups ( Fig.14 ,A) and lower DAI score ( Fig.14 ,B), at the same time, the experimental results also showed that Ep-TH also showed a significant protective effect on DSS-induced colorectal length reduction ( Fig.14 ,C). The spleen index of the Ep-TH group was significantly lower than that of the DSS group ( Fig.14 ,D), which indicates that Ep-TH can regulate immunity to inhibit inflammation. In summary, these results demonstrate that Ep-TH can exhibit significant preventive efficacy against DSS-induced colitis in mice.

[0227] The same method was used to test BL-TH and CB-TH, and both showed the same Fig.14 Similar results.

[0228] Example 8

[0229] The method in Example 1 was used to construct an engineered bacterium expressing the IL-23 antibody. The recombinant plasmid used was a recombinant plasmid obtained by replacing the TNF-α antibody encoding gene in pUC19-pelB-TNF-ClyA-HlpA with the IL-23 antibody encoding gene (SEQ ID NO: 12). The Escherichia coli engineered bacteria transferred into the plasmid were referred to as Ep-IH, the Bifidobacterium engineered bacteria transferred into the plasmid were referred to as BL-IH, and the Clostridium butyricum engineered bacteria transferred into the plasmid were referred to as CB-IH.

[0230] The same method as in Example 3 was used to test the efficacy of the above-mentioned engineered bacteria on UC, and similar experimental results were obtained. These findings indicate that the engineered bacteria provided by the present invention can also show significant efficacy in the mouse acute colitis model after replacing the anti-proinflammatory cytokine antibody encoding gene.

[0231] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. An engineered probiotic, characterized in that: The engineered probiotics include probiotics and a recombinant expression system introduced into the probiotics, wherein the recombinant expression system includes a gene encoding a cell surface display protein and a gene encoding a heparin sulfate proteoglycan specific adhesion protein.

2. The engineered probiotic according to claim 1, wherein The cell surface display protein encoding gene may encode a cell surface display protein derived from Streptococcus gallic acid (Streptococcus galloLyticus), preferably the cell surface display protein encoding gene may encode a cell surface display protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 1; Preferably, the cell surface displayed protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 2; and / or, the heparan sulfate proteoglycan-specific adhesion protein encoding gene may encode a heparan sulfate proteoglycan-specific adhesion protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 3; Preferably, the heparan sulfate proteoglycan-specific adhesion protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 4; Preferably, the recombinant expression system further comprises at least one of a promoter, a signal peptide encoding gene and an anti-pro-inflammatory cytokine antibody encoding gene; Preferably, the promoter comprises an arabinose promoter and / or a constitutive promoter, and preferably the nucleotide sequence of the arabinose promoter is as shown in SEQ ID NO: 5; Preferably, the constitutive promoter comprises P J23103 , P J23117 , P J23114 , P J23105 and P J23110 At least one of the constitutive promoters, preferably the constitutive promoter comprises a nucleotide sequence as shown in at least one of SEQ ID NOs: 6-10; More preferably, the constitutive promoter is P J23105 , whose nucleotide sequence is shown in SEQ ID NO:9; Preferably, the signal peptide encoding gene comprises a nucleotide sequence encoding at least one of the signal peptides pelB, bla and mglB, and preferably the signal peptide encoding gene can encode at least one of the amino acid sequences shown in SEQ ID NOs: 11-13; More preferably, the signal peptide encoding gene may encode the signal peptide pelB, and preferably the signal peptide encoding gene comprises the nucleotide sequence shown in SEQ ID NO: 14; More preferably, the anti-inflammatory cytokine antibody is selected from TNF-α antibody and / or IL-23 antibody, preferably, the anti-inflammatory cytokine antibody encoding gene can encode an antibody having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 15 or 16, and more preferably, the anti-inflammatory cytokine antibody encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 17 or 18.

3. The engineered probiotic according to claim 1 or 2, wherein: The probiotics are selected from at least one of Escherichia coli, Bifidobacterium and Clostridium butyricum; Preferably, the probiotic is selected from at least one of Escherichia coli Nissle1917, Bifidobacterium CICC 6071 and Clostridium butyricum CCTCCAB 2010154.

4. A method for constructing engineered probiotics, characterized in that: The method comprises introducing a recombinant expression system into probiotics, wherein the recombinant expression system comprises a gene encoding a cell surface display protein and a gene encoding a heparan sulfate proteoglycan specific adhesion protein.

5. The method according to claim 4, wherein: The cell surface display protein encoding gene may encode a cell surface display protein derived from Streptococcus gallic acid (Streptococcus galloLyticus), preferably the cell surface display protein encoding gene may encode a cell surface display protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 1; Preferably, the cell surface displayed protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 2; and / or, the heparan sulfate proteoglycan-specific adhesion protein encoding gene may encode a heparan sulfate proteoglycan-specific adhesion protein having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 3; Preferably, the heparan sulfate proteoglycan-specific adhesion protein encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 4; Preferably, the recombinant expression system further comprises at least one of a promoter, a signal peptide encoding gene and an anti-pro-inflammatory cytokine antibody encoding gene; More preferably, the promoter comprises an arabinose promoter and / or a constitutive promoter, and preferably the nucleotide sequence of the arabinose promoter is as shown in SEQ ID NO: 5; preferably the constitutive promoter comprises P J23103 , P J23117 , P J23114 , P J23105 and P J23110 At least one of, more preferably, the constitutive promoter comprises a nucleotide sequence as shown in at least one of SEQ ID NOs: 6-10; Further preferably, the constitutive promoter is P J23105 , whose nucleotide sequence is shown in SEQ ID NO:9; More preferably, the signal peptide encoding gene comprises a nucleotide sequence encoding at least one of the signal peptides pelB, bla and mglB, and preferably the signal peptide encoding gene can encode at least one of the amino acid sequences shown in SEQ ID NOs: 11-13; Further preferably, the signal peptide encoding gene includes an encoding signal peptide pelB, and preferably the signal peptide encoding gene includes a nucleotide sequence as shown in SEQ ID NO: 14; More preferably, the anti-inflammatory cytokine antibody is selected from TNF-α antibody and / or IL-23 antibody, preferably, the anti-inflammatory cytokine antibody encoding gene can encode an antibody having at least 60% identity with the amino acid sequence shown in SEQ ID NO: 15 or 16, more preferably, the anti-inflammatory cytokine antibody encoding gene has at least 50% identity with the nucleotide sequence shown in SEQ ID NO: 17 or 18; Preferably, the probiotics are selected from at least one of Escherichia coli, Bifidobacterium and Clostridium butyricum; More preferably, the probiotic is selected from at least one of Escherichia coli Nissle1917, Bifidobacterium CICC 6071 and Clostridium butyricum CCTCC AB 2010154.

6. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the engineered probiotic according to any one of claims 1 to 3 as an active ingredient, or the pharmaceutical composition comprises the engineered probiotic constructed according to the method of claim 4 or 5 as an active ingredient.

7. The pharmaceutical composition according to claim 6, wherein The pharmaceutical composition also includes other active ingredients; Preferably, the other active ingredients are selected from at least one of glucocorticoids, aminosalicylate, immunosuppressants and other probiotic preparations; And / or, the pharmaceutical composition further comprises excipients; Preferably, the auxiliary material includes at least one of a buffer, a protective agent, a stabilizer, a coating agent and a flavoring agent.

8. Use of the engineered probiotic according to any one of claims 1 to 3, or the engineered probiotic constructed according to the method of claim 4 or 5, or the pharmaceutical composition according to claim 6 or 7 in the preparation of a medicament for treating inflammatory bowel disease.

9. Use of the engineered probiotics according to any one of claims 1 to 3, or the engineered probiotics constructed according to the method of claim 4 or 5, or the pharmaceutical composition according to claim 6 or 7 in the preparation of drugs and / or functional health products, wherein: The medicine and / or functional health product is used to repair the intestinal barrier, and / or to improve the homeostasis of intestinal flora, and / or to regulate intestinal mucosal immunity.

10. Use of the engineered probiotic according to any one of claims 1 to 3, or the engineered probiotic constructed according to the method of claim 4 or 5, or the pharmaceutical composition according to claim 6 or 7 in improving the long-term efficacy of inflammatory bowel disease.

Citation Information

Cited By

  • Inflammation response type genetically engineered probiotics as well as preparation method and application thereof

    CN121495822A